Who Paid My Doc
Jeffrey Miller
Thoracic Surgery (Cardiothoracic Vascular Surgery) Atlanta, GA Medical Doctor
NPI 1740246586 CMS profile 169348
5665 Peachtree Dunwoody Rd Ne, Suite 200, Atlanta, GA 30342
General payments
$7,744
Research payments
$5,738
Ownership & investment interest
$0
Research they led as principal investigator
$869,636
Through program year 2025, Jeffrey Miller of Atlanta, GA is reported in the CMS Open Payments database as having received $7,744 across 53 general payments and $5,738 in research payments paid to them. Separately, studies naming them as principal investigator received $869,636 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 72nd percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $508 | 11 | |
| 2024 | General | $226 | 5 | |
| 2023 | General | $3,594 | 18 | |
| 2023 | Research | $5,738 | 1 | |
| 2022 | General | $308 | 4 | |
| 2020 | General | $1,411 | 2 | |
| 2019 | General | $1,697 | 13 |
Beside peers
- Jeffrey Miller
- Thoracic Surgery (Cardiothoracic Vascular Surgery) median
- Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
- National median
In program year 2025, general payments to Jeffrey Miller were reported at $508. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.
Show as a table
| Year | Jeffrey Miller | Thoracic Surgery (Cardiothoracic Vascular Surgery) median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,697 | $886 | $178–$3,167 | $163 |
| 2020 | $1,411 | $341 | $108–$1,605 | $114 |
| 2021 | $0 | $453 | $125–$1,886 | $132 |
| 2022 | $308 | $695 | $180–$2,566 | $149 |
| 2023 | $3,594 | $745 | $205–$2,662 | $160 |
| 2024 | $226 | $799 | $214–$2,967 | $164 |
| 2025 | $508 | $791 | $208–$3,074 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 13 drugsPart D claims
406
Drug cost
$25,174
Branded share of claims
22.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 36 | $22,829 | |
| Doxycycline Monohydrate | Generic | 26 | $368 | |
| Oxycodone Hcl | Generic | 61 | $343 | |
| Diltiazem 24hr Er (Cd) Diltiazem Hcl | Brand | 20 | $283 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 36 | $278 | |
| Amiodarone Hcl | Generic | 19 | $244 | |
| Atorvastatin Calcium | Generic | 38 | $207 | |
| Metoprolol Tartrate | Generic | 63 | $190 | |
| Famotidine | Generic | 15 | $126 | |
| Potassium Chloride | Generic | 23 | $124 |
The 10 drugs with the highest cost, of 13 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 411 Part D prescribers listed as Cardiac Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 39 billing codesPaid by Medicare
$206,443
Medicare patients
180
Services billed
491
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 70% | |
| Heart failure | 46% | |
| Arthritis | 43% | |
| Atrial fibrillation | 41% | |
| Diabetes | 38% | |
| Chronic kidney disease | 29% | |
| COPD | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
54 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Thoracic Surgery (Cardiothoracic Vascular Surgery) in Georgia
Jeremy London
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Savannah, GA
Vinod Thourani
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Marietta, GA
Manu Sancheti
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Atlanta, GA
John Puskas
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Atlanta, GA
Douglas Murphy
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Atlanta, GA
Daniel Miller
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Marietta, GA
Related records
Thoracic Surgery (Cardiothoracic Vascular Surgery) in Georgia
Practitioners in the same specialty and state, ranked by reported value.
All Thoracic Surgery (Cardiothoracic Vascular Surgery)
Everyone recorded under this specialty, nationwide.
Doctors in Georgia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.